COMPUTED DESCRIPTORS
| Molecular Weight | 3369.8 g/mol |
|---|---|
| XLogP3 | -16.7 |
| Hydrogen Bond Donor Count | 45 |
| Hydrogen Bond Acceptor Count | 52 |
| Rotatable Bond Count | 109 |
| Exact Mass | 3368.6904307 g/mol |
| Monoisotopic Mass | 3367.6870759 g/mol |
| Topological Polar Surface Area | 1420 Ų |
| Heavy Atom Count | 237 |
| Formal Charge | 0 |
| Complexity | 8000 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 29 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently-Bonded Unit Count | 1 |
| Compound Is Canonicalized | Yes |
PRODUCT INTRODUCTION
description
Avexitide is a truncated form of the glucagon-like peptide 1 receptor (GLP-1R) agonist exendin-4 peptide, with GLP-1 receptor (GLP-1R) antagonistic and GLP-1R-mediated signaling inhibiting activities. Upon administration, avexitide competitively binds to and inhibits the activity of GLP-1R, thereby inhibiting GLP-1/GLP-1R-mediated signaling. This antagonizes the glucagonostatic and the insulinotropic effects of GLP-1. By abrogating GLP-1-mediated simulation of insulin release and reduction of glucagon secretion after food intake, exendin 9-39 may be used to help study the potential effects of overproduction of GLP-1 on food intake, weight loss and glucose levels. GLP-1R, located on pancreatic beta cells, is overexpressed on certain tumor cell types. GLP-1 is a gastrointestinal (GI) and insulinotropic hormone that is released after a meal and plays a key role in the regulation of blood glucose levels.